Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170664
Status:
COMPLETED
Last Update Posted:
2016-03-25
First Post:
2005-09-12
Brief Title:
Taxol Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
Sponsor:
North Eastern German Society of Gynaecological Oncology
Organization:
North Eastern German Society of Gynaecological Oncology
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer Based on a phase I study now a multi-center phase II-trial was conducted
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None